Gilda Tachedjian Australian Society for Microbiology Annual Scientific Meeting 2013

Gilda Tachedjian

A/Prof Gilda Tachedjian is a Principal Burnet Fellow and Head of the Retroviral Biology and Antivirals Laboratory at the Burnet Institute. She was awarded her PhD in 1997 (Monash University) and received a National Health and Medical Research Council (NHMRC) CJ Martin Fellowship to undertake postdoctoral studies at Columbia University with Prof. Stephen Goff on retroviral replication. In 2002 she was recruited to the Burnet Institute and was awarded a NHMRC RD Wright Career Development Award in 2003 and a NHMRC Senior Research Fellowship in 2009. A/Prof Tachedjian is a virologist with an interest in both basic research and translational studies. Her current research interests include understanding Retroviral Biology including elucidating the role of the reverse transcriptase domain in the late stages of the life-cycle, the identification and characterization of retroviruses and intracellular restriction factors in bats, antiviral drugs and drug resistance, and the prevention of HIV and other sexually transmitted infections in the female genital tract. Her major contributions to the field include identifying mutations in the HIV-1 reverse transcriptase that confer resistance to antiretroviral drugs that are now incorporated in genotyping algorithms for predicting HIV drug resistance. She developed a yeast-two hybrid assay for studying RT dimerization, which was patented and led to the discovery that potent nonnucleoside RT inhibitors enhance RT subunit interaction. She has played a major role in the preclinical development of topical microbicides and in completing a phase I clinical study (SPL7013-003) to determine the retention of the dendrimer microbicide VivaGel® after vaginal dosing in healthy women. A/Prof Tachedjian has over 60 publications and she has presented her research at over 50 major national and 47 international conferences/seminars. Two of her publications received commentaries in PLoS Medicine and PNAS. She has received competitive funding since 1997 from NHMRC, NIH, ACH2 and the Prostate Cancer Foundation of Australia. She is on the Editorial Board of PLoS One, Current HIV Research, AIDS Research and Human Retroviruses and regularly reviews articles for Antimicrobial Agents and Chemotherapy.

Abstracts this author is presenting: